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Abstract
The antimicrobial peptide CAP18 has been
demonstrated to have a strong in vitro bactericidal
effect on Yersinia ruckeri, but its activity in vivo
has not been described. In this work, we investi-
gated whether CAP18 protects rainbow trout
Oncorhynchus mykiss (Walbaum) against enteric
red mouth disease caused by this pathogen either
following i.p. injection or by oral administration
(in feed). It was found that injection of CAP18
into juvenile rainbow trout before exposure to Y.
ruckeri was associated with lowered mortality com-
pared to non-medicated fish although it was less
effective than the conventional antibiotic oxolinic
acid. Oral administration of CAP18 to trout did
not prevent infection. The proteolytic effect of
secretions on the peptide CAP18 in the fish gas-
trointestinal tract is suggested to account for the
inferior effect of oral administration.
Keywords: antimicrobial peptide, CAP18, rainbow
trout, Yersinia ruckeri.
Introduction
Antimicrobial peptides (AMPs) are small proteins
(<40 amino acids) with a potential to eliminate a
wide range of pathogenic microorganisms. They
are encoded in the genomes of both vertebrates
and invertebrates (Zasloff 2002; Noga et al. 2011)
and act as important components of the innate
immune system primarily by killing pathogens
through disruption of the bacterial membrane
although they also may display immunomodula-
tory activities (Ganz 2003; Hancock & Sahl
2006). A large number of these peptides have been
identified in several fish species (Uzzell et al. 2003;
Chang et al. 2005; Chang et al. 2006; Maier
et al. 2008; Smith & Fernandes 2009; Rajanbabu
& Chen 2011; Masso-Silva & Diamond 2014)
suggesting an evolutionary old role in immunity.
Following extensive usage of antibiotics in human
and veterinary medicine for decades emergence of
antibiotic resistance in a series of bacterial patho-
gens, some which may infect fish, has been
recorded (Cabello 2006). This has raised growing
concern for future control of fish diseases and new
and alternative antimicrobial peptides with a thera-
peutic potential have therefore been in focus (Jia
et al. 2000; Douglas 2011). It is noteworthy that
development of bacterial resistance to these
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peptides is less readily developed compared to con-
ventional antibiotics (Steinberg et al. 1997;
Cabello 2006; Noga et al. 2011). A range of syn-
thetic antimicrobial peptides have been developed
and clinically tested but only a limited number of
them have confirmed the expected efficacy (Han-
cock & Sahl 2006; Zhang & Falla 2006). In addi-
tion, a limitation associated with the use of these
peptides as antibiotics is the potential cytotoxicity
associated with systemic application. Finally some
of the peptides are not resistant to proteases poten-
tially losing their function following oral adminis-
tration (Travis et al. 2000; Hancock & Sahl
2006). AMP application for control and treatment
of yersiniosis in rainbow trout Oncorhynchus mykiss
(Walbaum) has not been investigated previously.
Therefore, the present study was undertaken to
elucidate if a synthetic AMP, belonging to the
cathelicidin family, has an antibiotic effect against
Yersinia ruckeri infection in rainbow trout. We
investigated three synthetic broad-spectrum antimi-
crobial peptides (CAP11, CAP11-1-18 m2 and
CAP18) which recently have shown in vitro effect
against Y. ruckeri (Ebbensgaard et al. 2015). Prior
to the in vivo experiment, the cytotoxicity of these
peptides for fish cells (rainbow trout red blood
cells) was assessed in a haemolytic assay and the
non-toxic AMP (CAP18) was selected for further
in vivo work comparing administration methods
(intraperitoneal AMP injection and oral AMP
administration in feed). Different groups of rain-
bow trout receiving CAP18 were then exposed to
Y. ruckeri infection (1-h bath challenge) and the
disease progression was subsequently recorded and
compared to non-medicated control fish and fish
receiving a conventional antibiotic (oxolinic acid).
Materials and methods
Cathelicidin peptides CAP11 (94.7% purity),
CAP11-1-18 m2 (87.9% purity) and CAP18
(89.5% purity), were designed and synthesized by
GenScript (USA). These AMPs showed generally
high in vitro antimicrobial activities, that is
minimum inhibitory concentration (MIC) value
of 2–64 mg L1, against Gram-negative bacteria
including Y. ruckeri (Ebbensgaard et al. 2015).
Haemolysis assay
The cytotoxicity of these AMPs was determined
by measuring the released haemoglobin from
rainbow trout red blood cells. Blood samples were
collected by caudal vein puncture from rainbow
trout juveniles (10–12 g) using heparinized syr-
inges and transferred to Eppendorf tubes each
containing 100 lL heparin. The blood sample
was diluted with PBS and centrifuged at 4696 g
for 5 min. The supernatant was discarded and
RBC resuspended in PBS containing 100 lL hep-
arin whereupon the cell number was adjusted to
106 cells mL1. Dilution series (1:10–1:1000) of
antimicrobial peptides CAP11, CAP11-1-18m2
and CAP18 (all in basic concentrations of
10 mg mL1) were prepared in a 96-well plate,
and 100 lL of the RBC suspension was added to
each well, which was then incubated at room tem-
perature (18 °C) in an orbital shaker (50 rpm)
for 1 h. The plate was subsequently centrifuged at
4696 g for 5 min, and the supernatant (100 lL)
was transferred to another plate and read at
540 nm in ELISA plate reader, Epoch Microplate
Spectrophotometer (Holm & Halby), to measure
released haemoglobin. Triton X-100 (0.2%) was
used as positive control, as it caused 100%
haemolysis, and PBS was applied as negative con-
trol. CAP18 and CAP11-1-18m2 were dissolved
in water, while dimethyl sulphoxide (DMSO) was
used for dissolving CAP11. Therefore, not only
PBS but also DMSO was tested alone to examine
the effect of this solvent on fish RBCs.
Infection experiments
Based on the results of the haemolytic assay,
CAP18 was selected because it showed the lowest
haemolytic effect on fish RBCs making it the best
candidate for further in vivo experiments. Two
experiments were performed to determine the
functional effective dose of CAP18. This was fol-
lowed by two main experiments where the selected
dose of CAP18 was used on a larger number of
fish. For these trials, administration by intraperi-
toneal (i.p.) injection and the oral route (in feed)
were tested.
Experimental fish
For all experiments, we used rainbow trout (Fous-
ing strain) fry (2-5 g), hatched and reared in a
pathogen-free facility at the Salmon Hatchery,
Bornholm, Denmark (Xueqin, Kania & Buch-
mann 2012). Fish were transported to the univer-
sity fish-keeping facility, Copenhagen, Denmark,
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and acclimatized for 1–2 weeks before experimen-
tation. Upon arrival at the university fish-keeping
unit, the pathogen-free status of fish was con-
firmed by examining 2–3 fish for bacterial (head
kidney swabs) and parasitic infection (Buchmann
2007). During the acclimatization period, water
temperature was slowly increased until the desired
temperature of 15–16 °C and a light–dark scheme
(12/12-h light/dark) was attained. Fish were fed
(1.5% of biomass per day) with commercial stan-
dard pelleted feed (Inicio 917; BioMar A/S) until
challenge.
Dose adjustment experiments for i.p. injection of
CAP18. In the first experiment, rainbow trout
fry were anaesthetized in MS222 (50 mg L1)
(Sigma–Aldrich) and intraperitoneally injected
with 0.1 mL of an aqueous solution containing
different amounts of the antimicrobial peptide
CAP18, that is 50 lg, 100 lg, 200 lg and
400 lg per fish. Control fish were only injected
with sterile distilled water. Fish from all the
groups were stocked together in the same aquaria,
and tagging of different groups of fish was per-
formed by partial fin clipping (upper caudal fin,
lower caudal fin or adipose fin). One hour post-
injection with CAP18, fish were challenged by
bath exposure to Y. ruckeri O1 biotype 2
(5.6 9 108 CFU mL1) for 1 h. Subsequently,
fish were transferred to clean water and main-
tained until 15 days post-infection (dpi). The fish
were examined every second hour, and moribund
fish were removed and killed in a lethal overdose
of MS222 (300 mg L1) (according to the animal
welfare guidelines of the University of Copen-
hagen, Denmark).
Efficacy testing experiment. According to the
results from the preliminary experiments, the
effective dose of 400 lg CAP18 per fish was
selected for the main experiment. Groups of fish
receiving the antibiotic oxolinic acid (at 200 mg
kg1 body weight) were included as positive con-
trols. A total of six treatments groups with repli-
cate tanks for each group were set up. Rainbow
trout fry were anaesthetized in MS222 and
intraperitoneally injected (0.1 mL) with the
antimicrobial peptide CAP18 (400 lg per fish) or
the antibiotic oxolinic acid (200 mg kg1 body
weight). One hour post-injection with AMP or
oxolinic acid, fish were challenged by bath expo-
sure to Y. ruckeri O1 biotype 2 (4 9 106 CFU
mL1) in 5 L water volume for 6 h, and then,
the fish tank water level was raised up to 20 L
diluting the bacterial concentration to
1 9 106 CFU mL1. Fish were allowed to swim
in this bacterial solution for 18 h after which
water was totally replaced with fresh tap water
and fish were maintained until 14 dpi. The fish
were examined every second hour, and moribund
fish were killed and recorded. Three control
groups comprising unmedicated fish, CAP18-
injected fish and oxolinic acid-injected fish were
kept uninfected.
Oral administration (CAP18 in feed)
Based on the results of the i.p. injection experi-
ment, the dose of 400 lg CAP18 per fish was
chosen for the in-feed-based delivery of AMP.
Due to the risk of proteolytic degradation of
AMPs in the fish digestive tract and risk of
CAP18 leaching into the water, we also tested a
higher dose, 800 lg CAP18 per fish. Eight experi-
mental groups with replicate tanks were used. Fish
were fed (1.5% of biomass) with different diets
during the experiment. The uninfected and
infected control fish were fed commercial standard
non-medicated feed (BioMar A/S) during the
entire experiment.
The feed composition for the different treat-
ment groups is shown in Table 1. The positive
control, receiving conventional antibiotic, was fed
with commercial standard feed until challenge but
received oxolinic acid containing feed from the
day of challenge until 14 dpi. Four groups were
fed with CAP18-coated feed, and they all received
this diet from a week prior to challenge. One
group was fed with a dose of 400 lg g1 feed for
only 1 week until challenge, after which the fish
were offered non-medicated feed. A second group
Table 1 Composition of feed in the different treatment groups
and resulting mortality following Yersinia ruckeri challenge
(bath exposure)
Groups Survival (%)
Infected unmedicated control 50
CAP18-coated feed (400 lg g1) [for 1 week] 54
CAP18-coated feed (400 lg g1) [for 3 weeks] 48
CAP18-coated feed (800 lg g1) [for 1 week] 38
CAP18-coated feed (800 lg g1) [for 3 weeks] 58
Oxolinic acid-coated feed (1.25 g kg1 feed) 98
CAP18 injection (400 lg fish1) 58
Uninfected control 100
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was fed with the same dose for 3 weeks; that is,
feeding was continued after challenge until the
end of the experiment. The remaining two groups
were fed with the high dose, 800 lg g1 feed,
correspondingly.
Preparation of medicated feed
To avoid leaching of CAP18 from the pellets into
the tank water during feeding, the feed was top-
coated with CAP18 and fish oil under vacuum
allowing the AMP/oil to penetrate pores in the feed
pellet. Dry powder of oxolinic acid (1.25 g kg1
feed) was mixed with fish oil (at room tempera-
ture), and feed was top-coated by spraying the mix-
ture on 1.5-mm pelleted feed (BioMar A/S) while
stirring. The medicated feed was stored at 4 °C.
Challenge of fish receiving CAP18 in feed
After 7 days of feeding with CAP18-coated feed,
fish were challenged. Fish from all groups (except
uninfected control fish) were challenged by bath
exposure to Y. ruckeri O1 biotype 2
(1 9 106 CFU mL1) by the procedure described
above for efficacy testing. The fish were examined
every second hour, and moribund fish were
removed, killed and recorded. Water temperature
was measured on a daily basis in the course of
experiment with a mean of 15 °C. In all infection
experiments, bacteria were re-isolated on blood
agar (head kidney swabs) from moribund fish (2
fish per tank) to confirm that the bacterium caus-
ing disease was identical to the challenge strain.
Data analysis
Mortality in the experimental groups is presented
as cumulative mortality. Differences among mor-
tality of different groups were tested using
Kaplan–Meier plots and one-way ANOVA with




The antimicrobial peptide CAP18 showed a mini-
mal haemolytic activity (15.4%) at 10-fold dilu-
tion, reducing to zero at further dilutions tested
in this study. The other antimicrobial peptides,
CAP11 and CAP11-1-18m2, showed a marked
haemolytic activity at 10-fold dilution (96.3% and
71.6%, respectively) although the haemolytic
activity of these antimicrobial peptides decreased
considerably at subsequent dilutions. The solvent
DMSO had an adverse effect on blood cells as it
elicited a haemolysis of 30% (Fig. 1). This com-
pound was only used as solvent for CAP11,
whereas other AMPs were dissolved in water. Due
to the low CAP18 toxicity, this peptide was
selected for further analysis.
In vivo experiments
Intraperitoneal injection. Preliminary experi-
ments. In the first challenge experiment with
Y. ruckeri, the highest survival (70%) was recorded
Figure 1 Haemolytic activity of different
antimicrobial peptides (CAP11, CAP11
mutant and CAP18) on rainbow trout red
blood cells (RBCs).
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in fish injected with 400 lg of CAP18 followed by
fish injected with 200 and 100 lg CAP18 (30%
survival). The mortality in the 200-lg CAP18
group did not stabilize during the experimental per-
iod and must be regarded as a minimum mortality.
The exposed but unmedicated control group
showed a survival of 20%, and all fish died in the
50-lg CAP18-injected group. The onset of mortal-
ity was delayed 1 day in the CAP18-injected group
compared to the control group (Fig. 2). Y. ruckeri
was isolated from all killed fish (removed due to
disease progression) following challenge.
Main experiment. In the Y. ruckeri infection, the
highest survival was recorded in the oxolinic acid-
injected group (80%) followed by the CAP18-
injected (37%) and the control group (13%).
Survival rates of fish groups receiving CAP18 and
oxolinic acid were significantly higher (P < 0.05)
than the control group (Fig. 3). No mortalities
were observed in na€ıve uninfected control group
during the course of the experiment (Fig. 3).
Y. ruckeri was isolated from all killed fish follow-
ing challenge.
Oral administration of CAP18
In the feeding experiment, the highest mortalities
were recorded in the group fed with CAP18
800 lg g1 for 1 week (62%), the group receiv-
ing CAP18 400 lg g1 for 3 weeks (52%) and
CAP18 400 lg g1 for 1 week and the infected
control (50%). The group fed with CAP18
800 lg g1 for 3 weeks had lower mortality rates
Figure 2 Cumulative mortality (%) of
rainbow trout fry intraperitoneally injected
with antimicrobial peptide CAP18 or
antibiotic oxolinic acid following exposure
to Y. ruckeri.
Figure 3 Cumulative mortality (%) of
rainbow trout fry intraperitoneally injected
with antimicrobial peptide CAP18 or
antibiotic oxolinic acid and bath-exposed
to Y. ruckeri.
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(42%). Fish receiving oxolinic acid group showed
the lowest mortality (2%) (Fig. 4; Table 1). There
was a delay in the onset of disease in the fish fed
with oxolinic acid-coated feed (5 dpi) compared
to the other groups (Fig. 4). No disease was
observed in na€ıve uninfected control group during
the course of the experiment. Mortality in the
oxolinic acid group was significantly lower
(P < 0.001) than in the other groups, while there
were no significant differences (P > 0.05) between
the mortality of the infected control and the other
treated groups. The slightly lowered mortality in
the CAP18-injected group (42%) compared to the
infected control (50%) was not significant
(P > 0.05) due to variation of the replicates (mor-
tality rates of 28% and 56%).
Discussion
In the present study, the chemotherapeutic poten-
tial in rainbow trout of three cathelicidin antimi-
crobial peptides, CAP11, CAP11-1-18m2 and
CAP18, was evaluated. It was previously shown
in vitro that these three AMPs have a bactericidal
effect (Ebbensgaard et al. 2015). However, cyto-
toxicity studies revealed that CAP11 and CAP11-
1-18m2 were able to elicit lysis of rainbow trout
RBCs after which these AMPs were excluded from
the study. Only CAP18 (18-kDa cationic antimi-
crobial protein originally isolated and described
from rabbit leucocytes) showed high bactericidal
activity and low cytotoxicity and was therefore
considered a suitable candidate for the in vivo
experiments. Earlier studies have also indicated
CAP18 to be a promising antimicrobial com-
pound among a range of cationic antimicrobial
proteins (Mason et al. 1997; Travis et al. 2000).
We tested both intraperitoneal and oral adminis-
tration of this antimicrobial peptide and compared
it with the action of a well-characterized antibi-
otic, oxolinic acid. Compared to the non-injected
fish, we found that intraperitoneal injection of
CAP18 was associated with a significantly lower
mortality of rainbow trout exposed to Y. ruckeri.
The antimicrobial activity was indicated and cor-
responded to the action of other AMPs shown to
protect fish against other Gram-negative bacteria
(Jia et al. 2000; Pan et al. 2007). When testing
oral delivery of CAP18, a high and prolonged
dose of 800 lg g1 applied for 3 weeks led to a
slightly higher survival than the other groups
orally treated with CAP18, although it was not
statistically significant (P > 0.05). In the feeding
experiment, fish received AMPs a week prior to
infection, but it was obvious that this administra-
tion method was not sufficient for prevention of
mortality associated with Y. ruckeri exposure. An
earlier study on oral administration of AMPs (epi-
necidin-1) starting 30 days before the experimen-
tal bacterial infection with Vibrio vulnificus
showed a significantly higher survival in host
fishes from 13 dpi (Pan et al. 2012). Thus, it can-
not be excluded that an even longer premedication
period based on the administration of CAP18 as
feed supplement could lead to improved effect
against Y. ruckeri. However, proteolytic
Figure 4 Cumulative mortality (%) of
rainbow trout fingerlings fed with
antimicrobial peptide CAP18 (400 lg g1
and 800 lg g1 feed) or antibiotic oxolinic
acid or injected with CAP18
(400 lg fish1) following exposure to
Y. ruckeri O1 biotype 2 by bath exposure
for 6 h.
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degradation in the fish gastrointestinal tract of the
peptides in feed is likely to play a role for the lim-
ited effect observed in the present experiment. As
these peptides are vulnerable to proteolytic degra-
dation in the gut environment, it may be sug-
gested that the orally administered CAP18 was
degraded following ingestion. Therefore, for future
studies it may be suggested to improve stability
and protease resistance of this peptide by adding
compounds such as chitosan or alginate to the
feed (Hancock & Sahl 2006; Douglas 2011). In
addition, although vacuum and oil coating was
used for optimizing AMP adhesion to feed pellets,
it cannot be excluded that part of the CAP18 lea-
ched from the feed following feeding. The subop-
timal effect of CAP18 when used in feed together
with the high cost of AMP compounds may at
present challenge usage of oral CAP18 administra-
tion in the aquaculture industry. In conclusion,
the results of this study showed that antimicrobial
treatment via intraperitoneal injection of CAP18
was associated with an increased survival in rain-
bow trout infected with Y. ruckeri, whereas oral
administration (in-feed administration) was
unsuccessful.
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